Victoria Werth

Phase 2: Development of an Endocannabinoid Microparticle Formulation for the Topical Treatment of Cutaneous Manifestations of Lupus Erythematosus

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R44

PI · $1M · Atticus Pharma Inc

Extracellular Vesicles as a Novel Mediator for Ultraviolet-B Light Induced Photoaging and Skin Inflammation.

Department of Veterans Affairs · I01

Contact PI · Philadelphia Va Medical Center

Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)

National Institute of Arthritis and Musculoskeletal and Skin Diseases · UC2

PI · $6.3M · New York University School of Medicine

A Nonpsychoactive Cannabinoid Receptor-2 Agonist to Treat Itch and Inflammation in Dermatomyositis

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01

Contact PI · $1.7M · University of Pennsylvania

A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus

Principal investigator · Recruiting · Phase 2

Victoria Werth

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Principal investigator · Completed · Phase 3

Corbus Pharmaceuticals Inc.

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Principal investigator · Terminated · Phase 2

Corbus Pharmaceuticals Inc.

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Principal investigator · Completed

University of Pennsylvania